share_log

Public Companies Are Changchun BCHT Biotechnology Co.'s (SHSE:688276) Biggest Owners and Were Hit After Market Cap Dropped CN¥683m

Public Companies Are Changchun BCHT Biotechnology Co.'s (SHSE:688276) Biggest Owners and Were Hit After Market Cap Dropped CN¥683m

公共公司是長春BCHT生物技術股份有限公司(SHSE: 688276)的最大股東,在市值下降6.83億元人民幣後受到打擊。
Simply Wall St ·  06/19 21:45

Key Insights

主要見解

  • Changchun BCHT Biotechnology's significant public companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • The top 2 shareholders own 67% of the company
  • Insider ownership in Changchun BCHT Biotechnology is 32%
  • 長春生物科技的顯著上市公司所有權表明,關鍵決策受到更大公衆股東的影響。
  • 前兩大股東擁有該公司67%的股份。
  • 長春生物科技內部所有權佔比32%。

To get a sense of who is truly in control of Changchun BCHT Biotechnology Co. (SHSE:688276), it is important to understand the ownership structure of the business. With 41% stake, public companies possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

要了解長春生物科技股份有限公司(SHSE: 688276)真正的控制權歸屬,理解業務的所有權結構是非常重要的。41%的股份最多由上市公司持有,換言之,這個群體從自己的投資中得到最多的利潤(或虧損)。

While insiders, who own 32% shares weren't spared from last week's CN¥683m market cap drop, public companies as a group suffered the maximum losses

儘管佔32%的內部股東也沒有幸免於上週6.83億元人民幣市值的下跌,作爲一個群體的上市公司卻遭受了最大的損失。

Let's take a closer look to see what the different types of shareholders can tell us about Changchun BCHT Biotechnology.

讓我們更近距離地觀察不同類型股東對長春生物科技的影響。

ownership-breakdown
SHSE:688276 Ownership Breakdown June 20th 2024
SHSE:688276所有權的分配已於2024年6月20日更新。

What Does The Institutional Ownership Tell Us About Changchun BCHT Biotechnology?

機構的持有情況能給我們什麼關於長春生物科技的信息?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

Changchun BCHT Biotechnology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Changchun BCHT Biotechnology's earnings history below. Of course, the future is what really matters.

長春生物科技已經有機構股東。的確,他們在公司中擁有可觀的股份。這可能意味着該公司在投資社區中具有一定的聲望。但是,最好不要過於依賴機構投資者所謂的認可。他們有時也會犯錯誤。如果多個機構同時改變他們對某支股票的看法,你可能會看到股價快速下跌。因此,值得看一下長春生物科技下面的收入歷史。當然,未來才是真正重要的。

earnings-and-revenue-growth
SHSE:688276 Earnings and Revenue Growth June 20th 2024
SHSE:688276的收入和營業收入增長已於2024年6月20日更新。

Changchun BCHT Biotechnology is not owned by hedge funds. Changchun High-Tech Industry (Group) Co., Ltd. is currently the largest shareholder, with 41% of shares outstanding. For context, the second largest shareholder holds about 25% of the shares outstanding, followed by an ownership of 5.1% by the third-largest shareholder. Wei Kong, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.

長春生物科技並未被對沖基金所擁有。長春高新(集團)有限責任公司目前是最大的股東,擁有41%的流通股,第二大股東持有約25%的流通股,第三大股東則持有5.1%的股份。股東中排名第二的魏控同樣是首席執行官的頭銜。

To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

爲了使我們的研究更有趣,我們發現前2名股東擁有該公司的大部分所有權,這意味着他們足夠強大,可以影響公司的決策。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

儘管研究公司機構所有權數據是有意義的,但了解分析師的情緒也很有意義,以了解市場的走向。因爲有很多分析師正在跟蹤這個股票,所以看看他們的預測可能是值得的。

Insider Ownership Of Changchun BCHT Biotechnology

長春生物科技的內部股東佔比相對較高。內部人持有價值40億元的股份,佔總流通股的1/3多——這是非常有意義的。大部分人會很高興看到管理層和內部人與他們一起投資。你可能希望查看這個免費的圖表,以觀察內部人最近的交易。

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間有所不同。我們的數據反映了個人內部人員,至少捕捉到董事會成員的記錄。公司管理人員向董事會報告,後者應該代表股東的利益。值得注意的是,有時高級管理人員自己也在董事會中。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部人士持股是一件好事。但是,在某些情況下,它會使其他股東更難以對董事會的決定進行問責。

Our most recent data indicates that insiders own a reasonable proportion of Changchun BCHT Biotechnology Co.. Insiders own CN¥4.0b worth of shares in the CN¥12b company. That's quite meaningful. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.

通常情況下,作爲個體投資者的普通公衆持有長春生物科技的12%股份。儘管這一持股量可能不足以在決策中左右橫跳,但他們仍然可以對公司政策產生集體影響。

General Public Ownership

一般大衆所有權

The general public, who are usually individual investors, hold a 12% stake in Changchun BCHT Biotechnology. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

我們可以看到,私營企業持有已發行股票的4.7%。私營企業可能是關聯方。有時內部人通過持有私營企業的股權,而不是作爲個體的股東,來參與上市公司的股權安排。雖然很難得出任何廣泛的結論,但這個領域值得進一步研究。

Private Company Ownership

私有公司的所有權

We can see that Private Companies own 4.7%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們可以看到,上市公司持有長春生物科技已發行股票的41%。儘管我們不能確定,但這很可能是一個策略性的投資。這些企業可能存在業務上的共同之處,或相互合作。

Public Company Ownership

上市公司所有權

We can see that public companies hold 41% of the Changchun BCHT Biotechnology shares on issue. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

儘管公司的所有權分佈很值得考慮,但還有其他更重要的因素。比如:我們發現了長春生物科技的1個警告信號,你該留意一下。

Next Steps:

下一步:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for Changchun BCHT Biotechnology you should be aware of.

雖然考慮到擁有一家公司的不同群體非常值得,但還有其他更重要的因素。例如:我們發現了長春BCHT生物技術的1個警告標誌,您應該知道。

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

但最終,決定該業務所有者將獲得多大利益的是未來而非過去。因此,我們認爲最好查看此免費報告,以了解分析師是否預測更光明的未來。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論